Comprehensive Stock Comparison
Compare Rigel Pharmaceuticals, Inc. (RIGL) vs Akari Therapeutics, Plc (AKTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | AKTX | Beta 0.63 vs RIGL's 0.86, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | RIGL | +50.7% vs AKTX's -72.9% |
| Efficiency (ROA) | RIGL | 46.7% ROA vs AKTX's -34.7%, ROIC 6.4% vs -172.5% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Rigel Pharmaceuticals is a biotechnology company that discovers and develops small molecule drugs for hematologic disorders, cancer, and rare immune diseases. It generates revenue primarily from sales of its FDA-approved drug Tavalisse for chronic immune thrombocytopenia, supplemented by milestone payments and royalties from partnership agreements. The company's competitive advantage lies in its specialized expertise in kinase inhibition—particularly spleen tyrosine kinase (SYK) targeting—and its focused pipeline addressing underserved hematologic and autoimmune conditions.
Akari Therapeutics is a clinical-stage biopharmaceutical company developing advanced therapies for autoimmune and inflammatory diseases. It generates no revenue currently — its business model depends on advancing its lead candidate nomacopan through clinical trials to eventually secure regulatory approvals and commercialization partnerships. The company's key advantage lies in nomacopan's dual mechanism of action targeting both complement and leukotriene pathways — a differentiated approach that could offer superior efficacy in treating complex inflammatory conditions.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
RIGL leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). AKTX leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
RIGL and AKTX operate at a comparable scale, with $282M and $0 in trailing revenue.
| Metric | RIGLRigel Pharmaceuti… | AKTXAkari Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $282M | $0 |
| EBITDAEarnings before interest/tax | $121M | -$17M |
| Net IncomeAfter-tax profit | $113M | -$16M |
| Free Cash FlowCash after capex | $68M | -$10M |
| Gross MarginGross profit ÷ Revenue | +93.1% | — |
| Operating MarginEBIT ÷ Revenue | +42.2% | — |
| Net MarginNet income ÷ Revenue | +40.2% | — |
| FCF MarginFCF ÷ Revenue | +24.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +25.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +108.1% | -80.2% |
Valuation Metrics
| Metric | RIGLRigel Pharmaceuti… | AKTXAkari Therapeutic… |
|---|---|---|
| Market CapShares × price | $615M | $12.6B |
| Enterprise ValueMkt cap + debt − cash | $618M | $12.6B |
| Trailing P/EPrice ÷ TTM EPS | 35.09x | -0.00x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.75x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 23.41x | — |
| Price / SalesMarket cap ÷ Revenue | 3.43x | — |
| Price / BookPrice ÷ Book value/share | 186.88x | 0.00x |
| Price / FCFMarket cap ÷ FCF | 19.80x | — |
Profitability & Efficiency
RIGL delivers a 96.3% return on equity — every $100 of shareholder capital generates $96 in annual profit, vs $-69 for AKTX. AKTX carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to RIGL's 18.24x. On the Piotroski fundamental quality scale (0–9), RIGL scores 7/9 vs AKTX's 3/9, reflecting strong financial health.
| Metric | RIGLRigel Pharmaceuti… | AKTXAkari Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | +96.3% | -69.4% |
| ROA (TTM)Return on assets | +46.7% | -34.7% |
| ROICReturn on invested capital | +6.4% | -172.5% |
| ROCEReturn on capital employed | +29.4% | -142.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 3 |
| Debt / EquityFinancial leverage | 18.24x | 0.15x |
| Net DebtTotal debt minus cash | $3M | $661,000 |
| Cash & Equiv.Liquid assets | $57M | $3M |
| Total DebtShort + long-term debt | $60M | $3M |
| Interest CoverageEBIT ÷ Interest expense | 16.09x | -47.14x |
Total Returns (with DRIP)
A $10,000 investment in RIGL five years ago would be worth $7,772 today (with dividends reinvested), compared to $35 for AKTX. Over the past 12 months, RIGL leads with a +50.7% total return vs AKTX's -72.9%. The 3-year compound annual growth rate (CAGR) favors RIGL at 32.0% vs AKTX's -67.5% — a key indicator of consistent wealth creation.
| Metric | RIGLRigel Pharmaceuti… | AKTXAkari Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | -16.9% | -18.6% |
| 1-Year ReturnPast 12 months | +50.7% | -72.9% |
| 3-Year ReturnCumulative with dividends | +130.1% | -96.6% |
| 5-Year ReturnCumulative with dividends | -22.3% | -99.6% |
| 10-Year ReturnCumulative with dividends | +53.0% | -99.9% |
| CAGR (3Y)Annualised 3-year return | +32.0% | -67.5% |
Risk & Volatility
AKTX is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than RIGL's 0.86 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RIGL currently trades 66.5% from its 52-week high vs AKTX's 13.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RIGLRigel Pharmaceuti… | AKTXAkari Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.86x | 0.63x |
| 52-Week HighHighest price in past year | $52.24 | $1.73 |
| 52-Week LowLowest price in past year | $15.50 | $0.22 |
| % of 52W HighCurrent price vs 52-week peak | +66.5% | +13.7% |
| RSI (14)Momentum oscillator 0–100 | 48.7 | 52.2 |
| Avg Volume (50D)Average daily shares traded | 347K | 387K |
Analyst Outlook
Wall Street rates RIGL as "Buy" and AKTX as "Buy". Consensus price targets imply 12601.1% upside for AKTX (target: $30) vs 15.1% for RIGL (target: $40).
| Metric | RIGLRigel Pharmaceuti… | AKTXAkari Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $40.00 | $30.00 |
| # AnalystsCovering analysts | 15 | 7 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 20 | Feb 26 | Change |
|---|---|---|---|
| Rigel Pharmaceutica… (RIGL) | 100 | 169.86 | +69.9% |
| Akari Therapeutics,… (AKTX) | 100 | 0.64 | -99.4% |
Rigel Pharmaceutica… (RIGL) returned -22% over 5 years vs Akari Therapeutics,… (AKTX)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Rigel Pharmaceutica… (RIGL) | $29M | $179M | +520.4% |
| Akari Therapeutics,… (AKTX) | $0.00 | $0.00 | — |
Rigel Pharmaceuticals, Inc.'s revenue grew from $29M (2015) to $179M (2024) — a 22.5% CAGR. Akari Therapeutics, Plc's revenue grew from $0M (2015) to $0M (2024) — a 0.0% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Rigel Pharmaceutica… (RIGL) | -5.82 | 0.99 | +117.0% |
| Akari Therapeutics,… (AKTX) | -10,640 | -1,660 | +84.4% |
Rigel Pharmaceuticals, Inc.'s EPS grew from $-5.82 (2015) to $0.99 (2024). Akari Therapeutics, Plc's EPS grew from $-10640.00 (2015) to $-1660.00 (2024).
Chart 4Free Cash Flow — 5 Years
Rigel Pharmaceuticals, Inc. generated $31M FCF in 2024 (+492% vs 2021). Akari Therapeutics, Plc generated $-13M FCF in 2024 (+33% vs 2021).
RIGL vs AKTX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RIGL or AKTX a better buy right now?
Rigel Pharmaceuticals, Inc. (RIGL) offers the better valuation at 35.1x trailing P/E (8.8x forward), making it the more compelling value choice. Analysts rate Rigel Pharmaceuticals, Inc. (RIGL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RIGL or AKTX?
Over the past 5 years, Rigel Pharmaceuticals, Inc. (RIGL) delivered a total return of -22.3%, compared to -99.6% for Akari Therapeutics, Plc (AKTX). A $10,000 investment in RIGL five years ago would be worth approximately $8K today (assuming dividends reinvested). Over 10 years, the gap is even starker: RIGL returned +53.0% versus AKTX's -99.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RIGL or AKTX?
By beta (market sensitivity over 5 years), Akari Therapeutics, Plc (AKTX) is the lower-risk stock at 0.63β versus Rigel Pharmaceuticals, Inc.'s 0.86β — meaning RIGL is approximately 36% more volatile than AKTX relative to the S&P 500. On balance sheet safety, Akari Therapeutics, Plc (AKTX) carries a lower debt/equity ratio of 15% versus 18% for Rigel Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — RIGL or AKTX?
Rigel Pharmaceuticals, Inc. (RIGL) is the more profitable company, earning 9.8% net margin versus 0.0% for Akari Therapeutics, Plc — meaning it keeps 9.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RIGL leads at 13.5% versus 0.0% for AKTX. At the gross margin level — before operating expenses — RIGL leads at 89.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is RIGL or AKTX more undervalued right now?
Analyst consensus price targets imply the most upside for AKTX: 12601.1% to $30.00.
06Which pays a better dividend — RIGL or AKTX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RIGL or AKTX better for a retirement portfolio?
For long-horizon retirement investors, Akari Therapeutics, Plc (AKTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.63)). Both have compounded well over 10 years (AKTX: -99.9%, RIGL: +53.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RIGL and AKTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.